drugset
drugset / Trial / NCT06367426

A Phase I Study of DDN-A-0101 in Healthy Volunteers and Elder People

NCT06367426 ↗

Phase 1 Unknown 100 enrolled Pharmacobio
RandomizedParallel-groupDouble-blindTreatment

Summary

The study is a Phase I, randomized double-blind, placebo-controlled, single and multiple dosing, dose-escalation study of the oral administration of DDN-A-0101 in healthy adults and elderly subjects

Timeline

Start
2024-04
Primary completion
2025-05
Completion
2025-05

Drugs

EvaluationDrugModalityDoseRoute
Subject DDN-A-0101 Unknown 150 mg Oral
Subject DDN-A-0101 Unknown 300 mg Oral
Subject DDN-A-0101 Unknown 450 mg Oral
Subject DDN-A-0101 Unknown 600 mg Oral
Subject DDN-A-0101 Unknown 900 mg Oral
Subject DDN-A-0101 Unknown 1200 mg Oral
Subject DDN-A-0101 Unknown 1500 mg Oral

Indications

Alzheimer disease